Hava Izci, MSc, PhD student, KU Leuven, Leuven, Belgium, discusses the correlation of Trop-2 expression with clinicopathological characteristics and outcome in triple-negative breast cancer (TNBC). Trop-2 is expressed in multiple cancers, including breast cancer (BC) and is currently used for targeting metastatic TNBC with antibody drug conjugates (ADCs). However, little is known about Trop-2 in the early setting of TNBC. To address this, information from approximately 500 patients from Belgium with TNBC who had received surgery or neoadjuvant chemotherapy were collected. Immunohistochemistry (IHC) of Trop-2 expression was performed to provide patients with a Trop-2 expression score of low, medium or high. Information on age, BMI, tumor grade, lymphovascular invasion (LVI), nodule involvement and histological subtype were also collected. Overall, higher Trop-2 expression was correlated with LVI and positive nodule involvement, as well as higher age at diagnosis. This interview took place at the San Antonio Breast Cancer Symposium 2021 in San Antonio.